<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087425</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000377250</org_study_id>
    <secondary_id>NIA-CII0301</secondary_id>
    <secondary_id>NCI-6216</secondary_id>
    <nct_id>NCT00087425</nct_id>
  </id_info>
  <brief_title>Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase II Trial Of Bryostatin-1 In Combination With Rituximab In Rituximab-Refractory Indolent B-cell Non Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as bryostatin 1, work in different ways to stop&#xD;
      cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as&#xD;
      rituximab can locate cancer cells and either kill them or deliver cancer-killing substances&#xD;
      to them without harming normal cells. Bryostatin 1 may help rituximab kill more cancer cells&#xD;
      by making them more sensitive to the drug.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bryostatin 1 together with rituximab&#xD;
      works in treating patients with B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia&#xD;
      that has not responded to previous treatment with rituximab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the feasibility and safety of bryostatin 1 and rituximab in patients with&#xD;
           rituximab-refractory indolent B-cell non-Hodgkin's lymphoma or chronic lymphocytic&#xD;
           leukemia (CLL).&#xD;
&#xD;
        -  Determine the antitumor response in patients treated with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the effects of this regimen on the functional and molecular status of effector&#xD;
           cells (i.e., NK cells, monocytes, and dendritic cells) in these patients.&#xD;
&#xD;
        -  Determine the expression of CD20 and complement-inhibitory molecules on tumor cells&#xD;
           before and after treatment with this regimen in these patients.&#xD;
&#xD;
        -  Determine the effects of this regimen on the global gene expression pattern in CLL cells&#xD;
           of these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive bryostatin 1 IV continuously over 24 hours on days -6, 2, and 9 of course 1&#xD;
      and on days 2 and 9 of courses 2-6. Patients also receive rituximab IV over 4 hours on days&#xD;
      1, 8, 15, and 22 of courses 1 and 4. Treatment repeats every 28 days for 6 courses in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 18-48 patients (9-24 with non-Hodgkin's lymphoma and 9-24&#xD;
      with chronic lymphocytic leukemia) will be accrued for this study within 12-30 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasability and safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumor response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional and molecular status of effector cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of CD20 and complement-inhibitory molecules on tumor cells before and after treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on global gene expression pattern in chronic lymphocytic leukemia cells</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bryostatin 1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following histologically or cytologically confirmed diseases:&#xD;
&#xD;
               -  Indolent B-cell non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
                    -  Stage II-IV disease&#xD;
&#xD;
               -  Chronic lymphocytic leukemia (CLL) meeting 1 of the following risk criteria:&#xD;
&#xD;
                    -  Intermediate-risk with progressive disease&#xD;
&#xD;
                    -  High-risk, modified Rai stage disease&#xD;
&#xD;
          -  CD20-positive by flow cytometry or immunohistochemistry&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Rituximab-refractory disease, defined as failure to achieve a response to the last&#xD;
             course of prior treatment with rituximab alone or in combination with other&#xD;
             therapeutic modalities&#xD;
&#xD;
          -  No known neoplastic leptomeningeal involvement and/or brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin normal (unless due to Gilbert's disease or organ involvement by NHL or CLL)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No history of anaphylaxis or immunoglobulin (Ig) E-mediated hypersensitivity to murine&#xD;
             protein&#xD;
&#xD;
               -  Prior infusion reactions to rituximab without an IgE component allowed&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Radiotherapy&#xD;
&#xD;
          -  At least 12 weeks since prior rituximab&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy and recovered&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent glucocorticoids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 12 weeks since prior radioimmunotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior therapy for the malignancy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Espinoza-Delgado, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gerontology Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIH - Warren Grant Magnuson Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>Waldenström macroglobulinemia</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bryostatin 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

